ARA-290 (Cibinetide) research guide
Erythropoietin-surface-inspired eleven-residue research peptide
How ARA-290 was developed from an erythropoietin structural surface, what small clinical studies measured, and why sample identity remains a separate question.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
ARA-290, also called cibinetide, is an eleven-amino-acid peptide developed from an erythropoietin structural motif. The design work concerned the outward-facing helix B surface rather than the entire protein. The molecule and a supplied research preparation still require their own identity evidence.
02 · Evidence position
What the literature can support
Preclinical design studies and small exploratory human trials investigate distinct questions. A condition-specific symptom signal cannot establish universal tissue repair, general pain relief or the safety and activity of a separate catalogue vial.
03 · Study-level map
Evidence and its limits
What was the design principle?
The 2008 work developed peptides inspired by the tertiary structure of erythropoietin and evaluated them in experimental injury models.
Limit: The design and experimental findings do not establish the effect of any material merely carrying the ARA-290 label.
Were all outcomes favourable in the early sarcoidosis trial?
A 2012 double-blind placebo-controlled pilot enrolled 22 participants. The small-fibre symptom score improved relative to placebo, while pain-intensity and fatigue scores improved similarly in both groups.
Limit: The small sample, selected condition and differing endpoints limit generalisation. The trial did not evaluate APS material.
Where is the cibinetide alias used?
A 2023 primary study names ARA290 as cibinetide and describes an eleven-amino-acid peptide while examining age-associated cardiac measures in rats.
Limit: An animal model does not establish a human healthspan effect or validate a supplied batch.
04 · Analytical context
Questions a batch record should answer
- 01Does the analytical record identify the expected peptide and terminal form rather than full-length erythropoietin?
- 02Does an identity result accompany the reported purity measurement?
- 03Are sample content, counter-ion and current stock traceability documented independently?
05 · Boundary conditions
What this record does not establish
- A molecular design objective is not a guaranteed product effect.
- Small, indication-specific pilot results leave broad efficacy and long-term safety unresolved.
- No verified APS CoA is available for the associated product at publication.
Sources checked
- 1.Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
Brines et al. — Proceedings of the National Academy of Sciences / PubMed Central · 2008 · Primary study
- 2.Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij et al. — Molecular Medicine / PubMed · 2012 · Primary study
- 3.A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan
Winicki et al. — Frontiers in Cardiovascular Medicine / PubMed Central · 2023 · Primary study